Multiple Sclerosis Atlas: A Molecular Map of Brain Lesion Stages in Progressive Multiple Sclerosis.

Network and systems medicine Pub Date : 2020-08-27 eCollection Date: 2020-01-01 DOI:10.1089/nsm.2020.0006
Tobias Frisch, Maria L Elkjaer, Richard Reynolds, Tanja Maria Michel, Tim Kacprowski, Mark Burton, Torben A Kruse, Mads Thomassen, Jan Baumbach, Zsolt Illes
{"title":"Multiple Sclerosis Atlas: A Molecular Map of Brain Lesion Stages in Progressive Multiple Sclerosis.","authors":"Tobias Frisch,&nbsp;Maria L Elkjaer,&nbsp;Richard Reynolds,&nbsp;Tanja Maria Michel,&nbsp;Tim Kacprowski,&nbsp;Mark Burton,&nbsp;Torben A Kruse,&nbsp;Mads Thomassen,&nbsp;Jan Baumbach,&nbsp;Zsolt Illes","doi":"10.1089/nsm.2020.0006","DOIUrl":null,"url":null,"abstract":"<p><p><b>Introduction:</b> Multiple sclerosis (MS) is a chronic disorder of the central nervous system with an untreatable late progressive phase. Molecular maps of different stages of brain lesion evolution in patients with progressive multiple sclerosis (PMS) are missing but critical for understanding disease development and to identify novel targets to halt progression. <b>Materials and Methods:</b> The MS Atlas database comprises comprehensive high-quality transcriptomic profiles of 98 white matter (WM) brain samples of different lesion types (normal-appearing WM [NAWM], active, chronic active, inactive, remyelinating) from ten progressive MS patients and 25 WM areas from five non-neurological diseased cases. <b>Results:</b> We introduce the first MS brain lesion atlas (msatlas.dk), developed to address the current challenges of understanding mechanisms driving the fate on a lesion basis. The MS Atlas gives means for testing research hypotheses, validating biomarkers and drug targets. It comes with a user-friendly web interface, and it fosters bioinformatic methods for <i>de novo</i> network enrichment to extract mechanistic markers for specific lesion types and pathway-based lesion type comparison. We describe examples of how the MS Atlas can be used to extract systems medicine signatures and demonstrate the interface of MS Atlas. <b>Conclusion:</b> This compendium of mechanistic PMS WM lesion profiles is an invaluable resource to fuel future MS research and a new basis for treatment development.</p>","PeriodicalId":74262,"journal":{"name":"Network and systems medicine","volume":" ","pages":"122-129"},"PeriodicalIF":0.0000,"publicationDate":"2020-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1089/nsm.2020.0006","citationCount":"10","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Network and systems medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1089/nsm.2020.0006","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2020/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 10

Abstract

Introduction: Multiple sclerosis (MS) is a chronic disorder of the central nervous system with an untreatable late progressive phase. Molecular maps of different stages of brain lesion evolution in patients with progressive multiple sclerosis (PMS) are missing but critical for understanding disease development and to identify novel targets to halt progression. Materials and Methods: The MS Atlas database comprises comprehensive high-quality transcriptomic profiles of 98 white matter (WM) brain samples of different lesion types (normal-appearing WM [NAWM], active, chronic active, inactive, remyelinating) from ten progressive MS patients and 25 WM areas from five non-neurological diseased cases. Results: We introduce the first MS brain lesion atlas (msatlas.dk), developed to address the current challenges of understanding mechanisms driving the fate on a lesion basis. The MS Atlas gives means for testing research hypotheses, validating biomarkers and drug targets. It comes with a user-friendly web interface, and it fosters bioinformatic methods for de novo network enrichment to extract mechanistic markers for specific lesion types and pathway-based lesion type comparison. We describe examples of how the MS Atlas can be used to extract systems medicine signatures and demonstrate the interface of MS Atlas. Conclusion: This compendium of mechanistic PMS WM lesion profiles is an invaluable resource to fuel future MS research and a new basis for treatment development.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
多发性硬化症图谱:进展性多发性硬化症脑损伤阶段的分子图谱。
简介:多发性硬化症(MS)是一种中枢神经系统的慢性疾病,具有不可治疗的晚期进展期。进行性多发性硬化症(PMS)患者脑病变进化不同阶段的分子图谱尚不清楚,但这对于了解疾病发展和确定阻止进展的新靶点至关重要。材料和方法:MS Atlas数据库包括来自10名进展性MS患者的98个不同病变类型(外观正常的WM [NAWM]、活动性、慢性活动性、非活动性、再髓鞘)的脑白质(WM)样本和来自5名非神经系统疾病患者的25个WM区域的全面高质量转录组学图谱。结果:我们介绍了第一个MS脑病变图谱(msatlas.dk),该图谱的开发旨在解决当前在病变基础上理解驱动命运机制的挑战。MS图谱为测试研究假设、验证生物标志物和药物靶点提供了手段。它带有一个用户友好的网络界面,它促进了生物信息学方法,用于从头开始的网络富集,以提取特定病变类型的机制标记和基于通路的病变类型比较。我们描述了如何使用MS Atlas提取系统医学签名的示例,并演示了MS Atlas的接口。结论:这一机制PMS WM病变概况汇编是推动未来MS研究的宝贵资源,并为治疗开发提供了新的基础。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
审稿时长
15 weeks
期刊最新文献
Integrative Data Analytic Framework to Enhance Cancer Precision Medicine. On the Consistency between Gene Expression and the Gene Regulatory Network of Corynebacterium glutamicum. An Early Stage Researcher's Primer on Systems Medicine Terminology. 2020 Peer Reviewer Thank You Plasma Metabolomic Signatures of Chronic Obstructive Pulmonary Disease and the Impact of Genetic Variants on Phenotype-Driven Modules.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1